NCT07150104View on ClinicalTrials.gov

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

April 17, 2025

Study Completion Date

March 11, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Nirogacestat

Nirogacestat will be administered.

DRUG

Pomalidomide

Pomalidomide will be administered.

DRUG

Dexamethasone

Dexamethasone will be administered.

Trial Locations (10)

44033

GSK Investigational Site, Ulsan

94805

GSK Investigational Site, Villejuif

41253-190

GSK Investigational Site, Salvador

90110-270

GSK Investigational Site, Porto Alegre

B3H 1V7

GSK Investigational Site, Halifax

01330

GSK Investigational Site, Mexico City

0450

GSK Investigational Site, Oslo

20-081

GSK Investigational Site, Lublin

03080

GSK Investigational Site, Seoul

SE-791 82

GSK Investigational Site, Falun

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY